Peloton Wealth Strategists Buys 550 Shares of Zoetis Inc. (NYSE:ZTS)

Peloton Wealth Strategists boosted its stake in shares of Zoetis Inc. (NYSE:ZTS) by 5.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 10,497 shares of the company’s stock after purchasing an additional 550 shares during the period. Peloton Wealth Strategists’ holdings in Zoetis were worth $1,710,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Atlantic Edge Private Wealth Management LLC boosted its stake in shares of Zoetis by 482.8% during the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock worth $28,000 after acquiring an additional 140 shares during the last quarter. Darwin Wealth Management LLC purchased a new position in shares of Zoetis during the 3rd quarter worth $31,000. First Personal Financial Services purchased a new position in shares of Zoetis during the 3rd quarter worth $33,000. Capital Performance Advisors LLP purchased a new position in shares of Zoetis during the 3rd quarter worth $33,000. Finally, Dunhill Financial LLC boosted its stake in shares of Zoetis by 80.6% during the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock worth $33,000 after acquiring an additional 75 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Insider Buying and Selling at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total value of $55,804.68. Following the sale, the executive vice president now directly owns 16,107 shares in the company, valued at approximately $2,757,196.26. The trade was a 1.98 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 0.16% of the stock is currently owned by insiders.

Zoetis Stock Performance

Shares of NYSE ZTS opened at $164.95 on Friday. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. The company has a market cap of $73.86 billion, a P/E ratio of 30.16, a P/E/G ratio of 2.78 and a beta of 0.90. The firm’s fifty day moving average is $166.25 and its two-hundred day moving average is $177.49. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $200.53.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.37 by $0.03. The company had revenue of $2.32 billion for the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. As a group, analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be issued a $0.50 dividend. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a yield of 1.21%. Zoetis’s dividend payout ratio is currently 36.56%.

Analysts Set New Price Targets

Several research analysts have recently weighed in on ZTS shares. Stifel Nicolaus dropped their price target on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. StockNews.com cut shares of Zoetis from a “buy” rating to a “hold” rating in a research note on Tuesday. Leerink Partners started coverage on shares of Zoetis in a research note on Monday, December 2nd. They set an “outperform” rating and a $215.00 price target on the stock. Barclays lifted their price target on shares of Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a research note on Friday, February 14th. Finally, Leerink Partnrs upgraded shares of Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. Two analysts have rated the stock with a hold rating, nine have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, Zoetis has a consensus rating of “Buy” and an average target price of $215.90.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.